{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:24:05Z","timestamp":1788967445361,"version":"build-2803163510"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.2169\/internalmedicine.3806-19","type":"journal-article","created":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T22:05:56Z","timestamp":1574028356000},"page":"657-662","source":"Crossref","is-referenced-by-count":13,"title":["Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib"],"prefix":"10.2169","volume":"59","author":[{"given":"Shuya","family":"Honda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Asahikawa-Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asahikawa-Kosei General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asahikawa-Kosei General Hospital, Japan"},{"name":"Department of Medicine, Division of Gastroenterology and Hematology\/Oncology, Asahikawa Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumu","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asahikawa-Kosei General Hospital, Japan"},{"name":"Department of Medicine, Division of Gastroenterology and Hematology\/Oncology, Asahikawa Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Asahikawa-Kosei General Hospital, Japan"},{"name":"Department of Medicine, Division of Gastroenterology and Hematology\/Oncology, Asahikawa Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hematology\/Oncology, Asahikawa Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.","DOI":"10.1056\/NEJMoa0708857"},{"key":"2","unstructured":"2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009."},{"key":"3","unstructured":"3. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389: 55-66, 2017."},{"key":"4","unstructured":"4. Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer 81: 17-25, 2017."},{"key":"5","unstructured":"5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 39: 1163-1173, 2018."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Obi S, Sato T, Sato S, et al. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int 13: 199-204, 2019.","DOI":"10.1007\/s12072-019-09929-4"},{"key":"7","unstructured":"7. Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 49: 111-117, 2019."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Aihara Y, Yoshiji H, Yamazaki M, et al. A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma. World J Gastrointest Oncol 4: 115-118, 2012.","DOI":"10.4251\/wjgo.v4.i5.115"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sanda M, Tamai H, Deguchi H, et al. Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. ISRN Gastroenterol 2011: 201529, 2011.","DOI":"10.5402\/2011\/201529"},{"key":"10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1592\/phco.27.5.775","volume":"27","author":"G de Lima Lopes","year":"2007","unstructured":"10. de Lima Lopes G Jr, Rocha Lima CM. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy 27: 775-777, 2007.","journal-title":"Pharmacotherapy Official Journal of the American College of Clinical Pharmacy","ISSN":"https:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. da Fonseca LG, Barroso-Sousa R, Sabbaga J, Hoff PM. Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Pract 4: 635, 2014.","DOI":"10.4081\/cp.2014.635"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gomez-Abuin G, Karam AA, Mezzadri NA, Bas CA. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer 7: 62-63, 2009.","DOI":"10.3816\/CGC.2009.n.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Date E, Okamoto K, Fumita S, Kaneda H. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Invest New Drugs 36: 350-353, 2018.","DOI":"10.1007\/s10637-017-0522-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14: 1860-1869, 2007.","DOI":"10.1245\/s10434-006-9337-9"},{"key":"15","unstructured":"15. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19: 577-582, 2008."},{"key":"16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E","volume":"7","author":"HA Edmondson","year":"1954","unstructured":"16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503, 1954.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(19830301)51:5<863::AID-CNCR2820510520>3.0.CO;2-D","volume":"51","author":"T Nakashima","year":"1983","unstructured":"17. Nakashima T, Okuda K, Kojiro M, et al. Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer 51: 863-877, 1983.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465, 2008.","DOI":"10.1158\/1078-0432.CCR-07-5270"},{"key":"19","unstructured":"19. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014: 638747, 2014."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18, 2014.","DOI":"10.1186\/2045-824X-6-18"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22: 115-128, 2009.","DOI":"10.1016\/j.beha.2009.01.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 130: 1270-1282, 2006.","DOI":"10.1053\/j.gastro.2005.12.034"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117: 4475-4483, 2011.","DOI":"10.1002\/cncr.25960"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Natsuizaka M, Omura T, Akaike T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 20: 1781-1787, 2005.","DOI":"10.1111\/j.1440-1746.2005.03919.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/5\/59_3806-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T03:21:15Z","timestamp":1583551275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/5\/59_3806-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3806-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}